Giá trị của điểm GALAD trong chẩn đoán ung thư gan nguyên phát trên đối tượng viêm gan, xơ gan

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Trọng Khoa Mai, Quang Hùng Nguyễn, Thành Trung Nguyễn, Thị Hoa Mai Nguyễn, Thuận Lợi Nguyễn, Cẩm Phương Phạm, Văn Thái Phạm, Thị Thúy Quỳnh Võ

Ngôn ngữ: vie

Ký hiệu phân loại: 616.36 *Diseases of biliary tract and liver

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2022

Mô tả vật lý: 258-266

Bộ sưu tập: Metadata

ID: 500645

Thêm vào giỏ

Đánh giá giá trị chẩn đoán ung thư biểu mô tế bào gan trên đối tượng nguy cơ cao bằng điểm GALAD. Đối tượng và phương pháp nghiên cứu: Nghiên cứu tiến cứu trên các đối tượng có nguy cơ cao mắc ung thư gan nguyên phát tại Bệnh viện Bạch Mai từ tháng 10 năm 2019 đến tháng 4 năm 2021. Kết quả nghiên cứu: 26,2% bệnh nhân xơ gan do viêm gan B, viêm gan C
73,8% bệnh nhân viêm gan virus không xơ gan hoặc xơ gan do các nguyên nhân khác. 136/572 bệnh nhân chẩn đoán ung thư biểu mô tế bào gan (23,8%), Trung vị giá trị AFP
AFP-L3
PIVKA-II ở nhóm bệnh nhân UTBMTBG là: 120,5ng/ml
11,2%
1233,0mAU/ml
cao hơn nhóm bệnh nhân không ung thư biểu mô tế bào gan là: 2,3ng/ml
0%
16mAU/ml (p <
0,000). Giá trị AFP, AFP-L3, PIVKA-II tăng khi kích thước khối u tăng (p <
0,001). Giá trị AFP, AFP-L3, PIVKA-II giai đoạn trung gian, muộn cao hơn bệnh giai đoạn sớm (p <
0,000). Giá trị AFP, PIVKA-II cao hơn ở nhóm có huyết khối tĩnh mạch cửa (p<
0,05). Sử dụng thang điểm GALAD chẩn đoán ung thư biểu mô tế bào gan cho diện tích dưới đường cong tốt nhất so với xét nghiệm bộ 3 riêng lẻ với AUC = 0,94
độ nhạy 91,9%
độ đặc hiệu 81,7%. Kết luận: Sử dụng thang điểm GALAD tăng tỷ lệ phát hiện ung thư biểu mô tế bào gan.To evaluate the diagnostic value of GALAD score for hepatocellular carcinoma detection among high-risk subjects. Patients and research methods: A prospective study was among high-risk subjects for primary liver cancer at Bach Mai Hospital from October 2019 to April 2021. Results: 26.2% of patients had cirrhosis due to hepatitis B, hepatitis C
73.8% of patients with viral hepatitis did not have cirrhosis or cirrhosis due to other causes. 136/572 patients were diagnosed with hepatocellular carcinoma (23.8%). Median AFP, AFP-L3 and PIVKA-II in the group of HCC patients were: 120.5ng/ml, 11.2% and 1233.0mAU/ml, respectively
these values is higher than the group of patients without hepatocellular carcinoma whose median AFP, AFP-L3 and PIVKA-II were 2.3ng/ml
0%
16mAU/ml, respectively (p<
0,000). AFP, AFP-L3, PIVKA-II values increased with the growth of tumor size (p<
0.001). The values of AFP, AFP-L3, PIVKA-II in intermediate and late stage of HCC were higher than those in early stage (p<
0.000). AFP, PIVKA-II values were higher in the group with portal vein thrombosis (p<
0.05). With AUC = 0.94
sensitivity = 91.9% and specificity = 81.7%, the GALAD scale gave the best area under the curve compared with the single triple test in the diagnosis of HCC. Conclusion: Using the GALAD scale increases the detection rate of hepatocellular carcinoma.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR